Takeda Pharmaceutical Files 6-K for March 2025
Ticker: TKPHF · Form: 6-K · Filed: Mar 26, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Mar 26, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, foreign-private-issuer
TL;DR
Takeda filed its March 2025 6-K, confirming its foreign private issuer status and 20-F annual report filing.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on March 26, 2025, reporting as a foreign private issuer for the month of March 2025. The filing indicates Takeda is subject to the 1934 Act and will file annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.
Why It Matters
This filing is a routine report for foreign private issuers, providing an update on Takeda's regulatory status and reporting requirements with the SEC.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain material non-public information that would typically impact stock price.
Key Players & Entities
- TAKEDA PHARMACEUTICAL CO LTD (company) — Filer
- 0001395064-25-000038 (filing_id) — Accession Number
- 20250326 (date) — Filing Date
- 001-38757 (company_id) — SEC File Number
FAQ
What type of filing is this for Takeda Pharmaceutical Company Limited?
This is a Form 6-K, a Report of Foreign Private Issuer.
When was this Form 6-K filed?
The filing was made on March 26, 2025.
What is Takeda's SEC file number?
Takeda's SEC file number is 001-38757.
Does Takeda file annual reports under Form 20-F or 40-F?
Takeda indicates it files annual reports under Form 20-F.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668, Japan.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 26, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).